Pregabalin
Pregabalin Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Neuropathic pain — diabetic peripheral neuropathy (DPN) | Adults | Monotherapy | FDA Approved |
| Postherpetic neuralgia (PHN) | Adults | Monotherapy | FDA Approved |
| Neuropathic pain — spinal cord injury (SCI) | Adults | Monotherapy | FDA Approved |
| Fibromyalgia | Adults | Monotherapy | FDA Approved |
| Partial-onset seizures | Adults & pediatric ≥1 month | Adjunctive | FDA Approved |
Pregabalin received its initial FDA approval on December 30, 2004, simultaneously for DPN, PHN, and as adjunctive therapy for partial-onset seizures in adults. It was subsequently approved for fibromyalgia in June 2007 (the first drug FDA-approved for this indication), and for SCI neuropathic pain in June 2012. The pediatric partial-onset seizure indication was approved for ages 4 and older in May 2018, and later expanded to include patients as young as 1 month. Unlike gabapentin, pregabalin has linear pharmacokinetics with ≥90% bioavailability, making dosing more predictable.
Generalized anxiety disorder (GAD): EMA-approved in Europe but not FDA-approved; supported by multiple RCTs. Evidence quality: High.
Social anxiety disorder: Evidence from RCTs. Evidence quality: Moderate.
Restless legs syndrome: Gabapentin enacarbil (a separate product) is FDA-approved; pregabalin itself is off-label. Evidence quality: Moderate.
Chronic low back pain (neuropathic component): Mixed evidence. Evidence quality: Low.
Perioperative pain (multimodal analgesia): Pre-surgical dosing to reduce opioid requirements; conflicting evidence. Evidence quality: Low–Moderate.
Pregabalin Dosing
Neuropathic Pain — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| DPN — diabetic neuropathy | 50 mg TID (150 mg/day) | 100 mg TID (300 mg/day) | 300 mg/day | May increase to 300 mg/day within 1 week; 600 mg/day studied but no additional benefit and less well tolerated (FDA PI) Doses above 300 mg/day not recommended for DPN |
| PHN — postherpetic neuralgia | 75 mg BID or 50 mg TID (150 mg/day) | 150–300 mg BID (300–600 mg/day) | 600 mg/day | Increase to 300 mg/day within 1 week; may increase to 600 mg/day after 2–4 weeks if needed |
| SCI neuropathic pain | 75 mg BID (150 mg/day) | 150–300 mg BID (300–600 mg/day) | 600 mg/day | Increase to 300 mg/day within 1 week; may increase to 600 mg/day after 2–3 weeks |
Fibromyalgia — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Fibromyalgia | 75 mg BID (150 mg/day) | 150–225 mg BID (300–450 mg/day) | 450 mg/day | May increase to 225 mg/day within 1 week; then to 300 mg/day; then to 450 mg/day based on response Given BID (not TID); maximum 450 mg/day for fibromyalgia specifically |
Epilepsy — Adjunctive Therapy
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Partial-onset seizures — adults | 75 mg BID or 50 mg TID (150 mg/day) | 150–600 mg/day in BID or TID | 600 mg/day | May increase based on response and tolerability; effective dose range 150–600 mg/day |
| Partial-onset seizures — pediatric (≥4 to <17 y) | 2.5 mg/kg/day | 10 mg/kg/day in BID or TID | 600 mg/day | Maximum 150 mg/day at 2.5 mg/kg; maximum 600 mg/day at 10 mg/kg Weight-based dosing; patients <30 kg may need adjusted dosing |
| Partial-onset seizures — pediatric (1 month to <4 y) | 3.5 mg/kg/day (if <30 kg) | 14 mg/kg/day (if <30 kg) | 600 mg/day | Higher weight-based doses needed in younger children due to faster clearance FDA approval based on PK extrapolation + pediatric RCT data |
Renal Dosing Adjustments
| CrCl (mL/min) | Total Daily Dose | Dosing Schedule | Notes |
|---|---|---|---|
| ≥60 | 150–600 mg/day | BID or TID | Standard dosing; no adjustment needed |
| 30–59 | 75–300 mg/day | BID or TID | 50% of standard dose (FDA PI) |
| 15–29 | 25–150 mg/day | Once daily or BID | 25% of standard dose |
| <15 | 25–75 mg/day | Once daily | Substantially reduced; monitor closely for toxicity |
| Hemodialysis | Supplemental dose after each 4-hour session | ~50% cleared per 4-hour session; give 25–150 mg supplemental dose based on daily regimen (FDA PI Table 2) | |
Unlike gabapentin, pregabalin has linear pharmacokinetics with ≥90% bioavailability across its entire dose range, meaning that doubling the dose reliably doubles the plasma level. This eliminates the dosing unpredictability seen with gabapentin’s saturable absorption. Pregabalin also achieves steady state within 24–48 hours (vs 1–2 days for gabapentin), allowing a faster onset of efficacy — clinical trials showed significant pain relief as early as day 2. These PK advantages support an effective starting dose of 150 mg/day without the need for the slow uptitration required for gabapentin.
Pregabalin Pharmacology
Mechanism of Action
Pregabalin is a structural analog of GABA but does not bind to GABA receptors or directly modulate GABAergic neurotransmission. Its primary pharmacological target is the α2δ-1 subunit of presynaptic voltage-gated calcium channels. By binding with high affinity to this subunit, pregabalin reduces calcium influx at hyperexcited nerve terminals, thereby decreasing the release of excitatory neurotransmitters including glutamate, noradrenaline, substance P, and calcitonin gene-related peptide (CGRP). This mechanism underlies its analgesic, anticonvulsant, and anxiolytic properties. Pregabalin has approximately 6-fold higher binding affinity for the α2δ subunit compared to gabapentin, which contributes to its higher potency and lower required doses.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ≥90%, dose-independent; Tmax ~1 h (fasting), ~3 h (fed); linear pharmacokinetics; absorbed via LAT1 and additional carriers (not saturable unlike gabapentin) | Predictable dose-response relationship; can start at effective dose (150 mg/day) without slow titration; food delays but does not reduce total absorption |
| Distribution | Vd ~0.5 L/kg; not protein-bound (<1%); readily crosses blood-brain barrier via LAT1; crosses placenta; present in breast milk | No displacement interactions; no need for free-level monitoring; breastfeeding not recommended |
| Metabolism | Negligible (<2%); does not induce or inhibit CYP enzymes; no active metabolites | No hepatic drug interactions; safe in hepatic impairment; no CYP-related dose adjustments needed |
| Elimination | t½ ~6.3 h; >90% renal excretion as unchanged drug; clearance proportional to CrCl; effectively removed by hemodialysis | BID or TID dosing; dose reduction required per CrCl; supplemental dose after each 4-hour hemodialysis session; steady state in 24–48 h |
Pregabalin Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 8–45% | Most common adverse reaction; dose-dependent (e.g., 29% DPN at 300 mg/day, 38% epilepsy at 600 mg/day vs 9% placebo); persisted until last dose in 30% of affected patients |
| Somnolence | 4–28% | Dose-dependent (e.g., 13% DPN at 300 mg, 18% epilepsy at 600 mg vs 5% placebo); persisted until last dose in 42% of affected patients |
| Peripheral edema | 6–12% | 6% overall (vs 2% placebo); up to 12% at highest doses; higher incidence with concurrent thiazolidinediones (19%); not associated with cardiovascular deterioration in trials |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Weight gain | 4–9% | 9% gained ≥7% body weight (vs 2% placebo); dose- and duration-dependent; not limited to patients with edema |
| Dry mouth | 1–7% | Dose-related |
| Blurred vision | 1–12% | Dose-dependent; higher at ≥300 mg/day; usually reversible |
| Constipation | 3–5% | Increase dietary fiber and fluids |
| Euphoria | 1–12% | 4% overall (vs 1% placebo); up to 12% in some populations; basis for Schedule V classification; monitor for misuse |
| Thinking abnormal (concentration/attention) | 2–9% | Dose-dependent; includes difficulty concentrating, cognitive slowing, and language problems |
| Ataxia / balance disorder | 2–20% | Up to 20% at 600 mg/day in epilepsy trials; increases fall risk in elderly |
| Fatigue | 4–7% | Dose-related; most common during initial treatment |
| Increased appetite | 2–7% | Contributes to weight gain |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Angioedema | Rare (postmarketing) | Any time during treatment | Discontinue immediately; emergency treatment for airway compromise; do not rechallenge. |
| Respiratory depression (with opioids/CNS depressants) | Rare (postmarketing; life-threatening) | Variable | FDA warning: monitor respiratory status when co-prescribed with opioids or in patients with respiratory impairment; consider lower starting dose. |
| Rhabdomyolysis | Rare (postmarketing) | Variable | Discontinue if myopathy suspected; check CK levels; evaluate renal function. |
| Suicidal ideation (AED class effect) | 0.43% (AED class pooled) | Within first weeks to months | Monitor mood and behavior; AED class-wide FDA warning. |
| PR interval prolongation | 3–6 msec increase at ≥300 mg/day | Dose-related | Caution in patients with pre-existing PR prolongation or on other PR-prolonging medications; ECG if symptoms arise. |
| Withdrawal seizures / symptoms | Uncommon | Within days of abrupt cessation | Taper gradually over at least 1 week; withdrawal symptoms include insomnia, nausea, headache, diarrhea, anxiety, sweating. |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Dizziness | 3–6% | Most common reason across indications; dose-dependent |
| Somnolence | 2–3% | Second most common; often occurs during initial therapy |
| Ataxia (epilepsy trials) | ~4% | Higher-dose epilepsy trials only |
| Weight gain / edema | ~1% | Infrequent cause of discontinuation despite being common as a side effect |
Pregabalin is classified as Schedule V (DEA) due to its potential for euphoria and misuse. In clinical trials, 4% of pregabalin patients reported euphoria (vs 1% placebo), ranging up to 12% in some populations. In recreational drug user studies, pregabalin 450 mg single dose produced subjective ratings of euphoria comparable to diazepam 30 mg. Carefully evaluate patients for history of substance use disorder before prescribing, and monitor for dose escalation, drug-seeking behavior, and concurrent opioid or benzodiazepine misuse.
Pregabalin Drug Interactions
Pregabalin has one of the simplest drug interaction profiles of any neuroactive medication. It is not metabolized by CYP enzymes, does not induce or inhibit any metabolic pathways, and is not protein-bound. It has no pharmacokinetic interactions with other AEDs (carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, topiramate). Clinically relevant interactions are limited to additive pharmacodynamic effects with CNS depressants and additive edema/weight gain with thiazolidinediones.
Pregabalin Monitoring
- Renal FunctionBaseline, then periodically
RoutinePregabalin is >90% renally eliminated as unchanged drug. Clearance is directly proportional to CrCl. Dose adjustment is required for CrCl <60 mL/min. Especially important in elderly patients. - Weight & EdemaEach visit
Routine9% of patients gained ≥7% body weight. Monitor peripheral edema, particularly in patients receiving concurrent thiazolidinediones or with CHF. Weight gain is dose- and duration-dependent. - Sedation / CNS EffectsOngoing, especially with opioid co-administration
RoutineDizziness and somnolence are the most common adverse reactions and persisted until the last dose in 30% (dizziness) and 42% (somnolence) of affected patients. Monitor when combined with other CNS depressants. - Visual ChangesIf symptoms arise
Trigger-basedBlurred vision, diplopia, and visual field defects reported. Consider ophthalmologic evaluation if persistent visual disturbances develop. - Mood / SuicidalityEach visit
RoutineAED class-wide suicidality risk applies. Suicidal ideation and behavior have also been reported after discontinuation of pregabalin. - Signs of MisuseOngoing in at-risk populations
Trigger-basedSchedule V controlled substance with recognized abuse potential. Monitor for tolerance, dose escalation, drug-seeking behavior, and concurrent substance use (especially opioids and benzodiazepines). - CK LevelsIf myopathy suspected
Trigger-basedRare postmarketing reports of rhabdomyolysis. Check CK if patient develops unexplained muscle pain, tenderness, or weakness.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to pregabalin or any of its components (FDA PI Section 4)
Relative Contraindications (Specialist Input Recommended)
- NYHA Class III–IV heart failure — limited safety data; pregabalin can cause fluid retention and peripheral edema
- Active substance use disorder — Schedule V; documented euphoria and misuse potential
- Concurrent gabapentin — same mechanism, no additive benefit, increased adverse effects
Use with Caution
- Elderly patients — increased risk of dizziness, falls, ataxia, and edema due to age-related renal decline
- Renal impairment — dose reduction required per CrCl; accumulation increases CNS and other adverse effects
- Respiratory impairment — especially with concurrent opioids or benzodiazepines
- Pregnancy — may cause fetal harm (animal data); advise patients of potential risk
- Abrupt withdrawal — taper over at least 1 week; abrupt cessation can cause withdrawal symptoms and possibly seizures
Postmarketing reports of respiratory failure and coma have been associated with pregabalin use, particularly when co-administered with opioids or other CNS depressants, or in patients with underlying respiratory impairment. Monitor patients for respiratory depression when co-prescribing with CNS depressants.
All AEDs, including pregabalin, carry an increased risk of suicidal thoughts and behavior. Suicidal behavior and ideation have also been reported after discontinuation of pregabalin. Monitor patients for emergence of depression, suicidal ideation, or unusual behavioral changes.
Patient Counselling
Purpose of Therapy
Pregabalin is a medication that helps manage nerve pain, fibromyalgia pain, or seizures by calming overactive nerve signals. It is taken by mouth, usually two or three times a day, and should be taken consistently at the same times each day for best effect.
How to Take
Take pregabalin exactly as prescribed, with or without food. Swallow capsules whole. If using the oral solution, measure carefully with a proper measuring device. Do not stop taking pregabalin suddenly — your prescriber will help you taper the dose gradually to avoid withdrawal effects.
Sources
- Pfizer Inc / Viatris. LYRICA (pregabalin) Capsules and Oral Solution — Full Prescribing Information. Revised 2025. FDA LabelPrimary source for all FDA-approved indications, dosing, contraindications, warnings, adverse reaction incidence data, and renal dosing table.
- Pfizer Inc. LYRICA CR (pregabalin) Extended-Release Tablets — Full Prescribing Information. Revised 2025. FDA LabelSource for the extended-release formulation PK data and pain indication adverse event rates.
- Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274-1283. doi:10.1212/01.WNL.0000055433.55136.55Pivotal PHN trial demonstrating significant pain reduction with pregabalin 150–600 mg/day in a dose-dependent manner.
- Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264-1273. doi:10.1002/art.20983Key fibromyalgia trial establishing pregabalin 450 mg/day as superior to placebo with significant improvements in pain, sleep, and function.
- French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60(10):1631-1637. doi:10.1212/01.WNL.0000068024.20285.65Dose-finding adjunctive epilepsy trial demonstrating dose-dependent seizure reduction at 150–600 mg/day.
- Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0NeuPSIG systematic review: pregabalin NNT 7.7 (95% CI 6.5–9.4) for ≥50% neuropathic pain reduction; recommended as first-line treatment.
- National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings. Clinical Guideline CG173. Updated 2020. NICE CG173NICE guideline recommending pregabalin or gabapentin as initial pharmacological options for neuropathic pain.
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724EULAR guidelines noting pregabalin as a management option for fibromyalgia with a weak recommendation based on moderate evidence.
- Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137-150. doi:10.1016/j.eplepsyres.2006.09.008Definitive review of the α2δ subunit mechanism: high-affinity binding reduces calcium influx and excitatory neurotransmitter release.
- Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13-18. doi:10.1111/j.0013-9580.2004.455003.xComprehensive PK review: ≥90% bioavailability, t½ 6.3 h, linear kinetics, <2% metabolism, no protein binding — supporting predictable dosing.
- Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-669. doi:10.2165/11536200-000000000-00000Head-to-head PK comparison demonstrating pregabalin’s linear absorption and ≥90% bioavailability vs gabapentin’s saturable, dose-dependent absorption.
- Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277-283. doi:10.1177/0091270003251119Renal PK study establishing the dose adjustment recommendations for CrCl-based dosing and hemodialysis supplementation.
- Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-426. doi:10.1007/s40265-017-0700-xReview documenting pregabalin misuse patterns, euphoria reports, and the pharmacological basis for Schedule V classification.